Benzyl Alcohol and the 28-Day Multi-Dose Convention

Last reviewed 9 August 2026

Two figures dominate this subject and neither is what it is usually taken to be. The first is 0.9 per cent, the concentration of benzyl alcohol in the most widely marketed preserved diluent. The second is twenty-eight days. Both have documented origins in compendial text, and neither is a statement about anything dissolved into the liquid afterwards.

This page follows the preservative rather than the water; the two pharmacopoeial water articles are compared in Bacteriostatic Water vs Sterile Water. One pair of terms should be fixed first: single-dose and multiple-dose are container designations describing how many times a closure is expected to be entered. They are not quantities, and this page states none. Where injection or parenteral appears below, it is part of the name of a compendial article or of a pharmacopoeial category definition, quoted so that it can be checked against its source; none of it is an instruction.

The molecule, and the monograph that controls it

The excipient monograph is harmonised across the European, Japanese and United States pharmacopoeias; the Ph. Eur. text is monograph 0256. Two rows repay attention. The benzaldehyde limit is not a single number: the same substance is held to 0.15 per cent for general use and to 0.05 per cent where it is intended for parenteral applications. That limit, the peroxide value and the storage condition all point at one piece of chemistry — benzyl alcohol oxidises on standing, first to benzaldehyde and onward to benzoic acid. Kazemifard and colleagues (2003) determined benzaldehyde in marketed injectable formulations by capillary gas chromatography and reported levels in generic diclofenac and piroxicam products seven to fifteen times higher than in the reference products. A preserved diluent is a formulated liquid with a specification and a degradation pathway of its own. Solute-free water is not.

What “bacteriostatic” designates

The word is precise and is routinely over-read. A bacteriostatic concentration restricts proliferation; it does not kill, it is not a sterilant, and it does not render a contaminated container clean. Aseptic technique is what keeps a container clean. The preservative constrains what happens to organisms introduced in spite of it, over a defined window, against a defined challenge.

Mechanistically it acts on the membrane rather than on a metabolic target. Yano and colleagues (2016), working with Methylobacterium mesophilicum and giant vesicles as a model membrane system, reported that benzyl alcohol increased membrane fluidity, destabilised membrane structures and inactivated bacterial membrane proteins including an efflux pump. Meyer and colleagues (2007), reviewing preservative use across licensed parenteral products, reported that phenol and benzyl alcohol are the two most commonly used preservatives in peptide and protein products. USP General Chapter <51> is blunter about the trade-off than most secondary sources: All useful antimicrobial agents are toxic substances.

What the USP article specifies, and what it leaves to the label

The monograph Bacteriostatic Water for Injection defines the article as Water for Injection that is sterilised and suitably packaged, containing one or more suitable antimicrobial agents. It does not name benzyl alcohol and it does not fix a concentration. That is why the monograph obliges the name and proportion of the added agent to appear on the container, and why both 0.9% w/v (9 mg/mL) and 1.1% w/v (11 mg/mL) presentations are marketed under it: the approved US labelling for the article states that it contains 0.9% (9 mg/mL) or 1.1% (11 mg/mL) of benzyl alcohol added as a bacteriostatic preservative. The figure so often quoted as though it were part of the definition is a property of a particular product, which is why the label must state it.

The rest is cross-references — sterility, endotoxins, particulate matter, pH 4.5 to 7.0, glass containers not larger than 30 mL — plus the two that matter here: Antimicrobial Effectiveness Testing <51> and Antimicrobial Agents—Content <341>. The compendium raises the compatibility question itself rather than leaving it to be inferred: Use Bacteriostatic Water for Injection with due regard for the compatibility of the antimicrobial agent or agents it contains with the particular medicinal substance that is to be dissolved or diluted. Water for Injection, by contrast, contains no added substance. Presentation detail is in the bacteriostatic water and sterile water entries under reconstitution and consumables; what research-grade material is not manufactured to is taken up in endotoxin, sterility and “research grade”.

<341> then governs the number on the label. The manufacturer must determine the lowest level at which the preservative is effective and formulate so that this level is exceeded throughout shelf life, because the concentration may fall. In its own words: The quantitative label statement of the preservative content is not intended to mean that the labeled quantity is retained during the shelf life of the product; rather, it is a statement of the amount added, within process limits, and which is not exceeded by more than 20%.

Where the twenty-eight days comes from

USP <51>: the end of an observation window

The chapter divides compendial articles into four categories, of which Category 1 covers injections and other parenterals, otic, sterile nasal and ophthalmic products with aqueous bases. Five organisms are used — Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans and the Aspergillus at ATCC 16404 — the challenged preparation being brought to between 1 × 10⁵ and 1 × 10⁶ cfu/mL, held at 22.5 ± 2.5 °C and sampled at intervals.

For Category 1 the criteria are not less than a 1.0 log reduction from the initial calculated count at 7 days, not less than 3.0 log at 14 days, and no increase from the 14 days’ count at 28 days; for yeasts and moulds, no increase at 7, 14 and 28 days. No increase is defined as not more than 0.5 log₁₀ unit above the previous value. One sentence carries more weight than the criteria table: The procedures and acceptance criteria for effectiveness apply to a product in the original, sealed container in which it was distributed by the manufacturer. Twenty-eight days is the last sampling point of that test — the end of an observation window on an unopened article of a particular composition.

USP <797>: a convention for a re-entered closure

The sterile compounding chapter is short on conventionally manufactured containers: on initially entering or puncturing a multiple-dose container, it is not used for more than 28 days unless the manufacturer’s labelling specifies otherwise. Single-dose containers are handled differently again, with a limit measured in hours. For compounded multiple-dose preparations the period is the assigned beyond-use date or 28 days, whichever is shorter, and only where <51> testing establishes it — testing performed once for each unique formulation and each container closure system in which it is packaged.

The European position, which produces no fixed number at all

Ph. Eur. general text 5.1.3 is the European challenge test, and twenty-eight days appears there too as the final reading rather than as a shelf life. For parenteral, eye, intrauterine and intramammary preparations the A criteria are 2 log for bacteria at 6 hours, 3 log at 24 hours and no recovery at 28 days, with fungi at 2 log by 7 days; the B criteria, admissible in justified cases, are 1 log at 24 hours and 3 log at 7 days for bacteria and 1 log by 14 days for fungi. Two statements there matter more than the tables: preservatives must not be used as a substitute for good manufacturing practice, and a preservative’s efficacy can be increased or reduced by the active constituent, by the formulation it is incorporated into, or by the container and closure used.

The dosage-form monograph Ph. Eur. 0520, reproduced in the British Pharmacopoeia, supplies the container half: the label states the name and concentration of any added antimicrobial preservative, and, where a preparation is presented in a multidose container, the precautions for its administration and its storage between successive withdrawals are given; closures for multidose containers are elastic enough that the puncture reseals when the needle is withdrawn. What no European text does is issue twenty-eight days as a general figure. CPMP/QWP/2934/99 establishes an in-use shelf life per product, and CPMP/CVMP/QWP/115/95 requires preservative efficacy under simulated in-use conditions to be established for multidose presentations, noting that it varies with the preservative’s structure and concentration, the product’s pH, the initial contamination, the pack design and the storage temperature.

What the number is a property of

Three things, and a solute is not among them. A formulation as tested — <51> is run on a product, <797> requires it per unique formulation, 5.1.3 names the active constituent as a variable. A container closure system as tested — <797> requires testing per packaging configuration, 5.1.3 names the container and closure, 0520 specifies the resealing behaviour that makes repeated entry meaningful. And an unopened article as distributed, plus the interval <797> allows after it is first entered. The tested article and the mixture that results from dissolving something into it are not the same formulation.

Two clocks, routinely welded into one

The formulation that circulates in this category — that reconstituted material lasts twenty-eight days because the preserved vehicle keeps it — joins two unrelated questions. Microbial proliferation inside a re-entered container is one; chemical degradation of the dissolved solute is the other, on its own kinetics. Lai and Topp (1999) reviewed the reactions affecting peptides and proteins in the solid state, among them deamidation, peptide bond cleavage, oxidation and aggregation; Manning and colleagues (2010) reviewed instability in solution and in the dried state. None of those routes is an organism, and an antimicrobial agent has no mechanism against any of them — a subject set out in lyophilised and in-solution stability, and in lyophilisation, mannitol and cake appearance.

The corollary for the unpreserved article is cleaner than most pages admit: sterile water carries no preservative, so the convention has no application to it at all — not a shorter figure, no figure. The arithmetic is likewise indifferent, the benzyl alcohol concentration being a property of the diluent and unchanged by how much solid is dissolved into it. That is worked through in calculating concentration after reconstitution, and the reconstitution calculator on this site resolves vial strength and diluent volume into a concentration and nothing else — a volume, never a target amount.

That a preservative interacts with what it is in contact with has been measured. Roy and colleagues (2005) examined lyophilised recombinant human interleukin-1 receptor antagonist reconstituted with a bacteriostatic concentration (0.9% w/v) of benzyl alcohol in water and reported greater aggregation than on reconstitution with water alone. That is a folded protein in a defined buffer, and a short synthetic sequence does not present the same conformational landscape; where no study exists for a given sequence, that is an absence of data, not a finding of no effect.

And the concentration is not a constant

<341> says outright that preservative concentration may fall during shelf life, and two documented mechanisms account for most of it. The first is sorption into, and permeation through, the closure. Thakare and colleagues (2019) investigated a benzyl-alcohol-preserved diluent in a prefilled syringe showing a systematic decrease in preservative content through accelerated and stress stability programmes; they reported that benzyl alcohol binds to the rubber components to a degree that varies with the rubber’s properties, and used headspace gas chromatography–mass spectrometry to show that it can also traverse the elastomeric tip-cap. The question is not new — a series in the Journal of Pharmaceutical Sciences in 1962–63 addressed preservative loss from rubber-stoppered containers, its relationship to microbiological activity in multiple-dose vials, and the contribution of closure composition. The second mechanism is oxidation, which the excipient monograph anticipates by limiting benzaldehyde and setting a peroxide value.

The excipient is also not analytically invisible: its aromatic chromophore resolves as its own peak in reversed-phase HPLC with ultraviolet detection, so area-percent arithmetic on a solution made up in a preserved vehicle concerns a different mixture from the dry solid a certificate describes — a distinction developed in area percent and net peptide content and how to read a certificate of analysis.

Five readings that do not follow

1. “Twenty-eight days is how long reconstituted material lasts.” It is the last sampling point of <51> and the beyond-use convention of <797> for a re-entered closure — statements about a vehicle and its container.
2. “0.9% is part of the definition.” The article specifies one or more suitable antimicrobial agents and obliges the label to declare which and how much. Both 0.9% w/v and 1.1% w/v presentations are marketed under it, and the approved US labelling for the article prints both figures.
3. “The label figure states what is in the container today.” <341> says the opposite in terms: it is the amount added within process limits, and not exceeded by more than 20%, rather than a claim that the quantity is retained.
4. “The twenty-eight days transfers to whatever is dissolved in it.” <51> applies to the original, sealed container as distributed; <797> requires testing per unique formulation and per container closure system; 5.1.3 states that efficacy can be altered by the active constituent, the formulation, and the container and closure.
5. “It is a British Pharmacopoeia figure.” It is not. Ph. Eur. 5.1.3 uses twenty-eight days as a challenge test’s final reading, and the European framework sets an in-use period per product.

References

1. United States Pharmacopeia. General Chapter <51>, Antimicrobial Effectiveness Testing. Current USP–NF text, document USPNF_M98790_03_01, DOI 10.31003/USPNF_M98790_03_01; the “original, sealed container” sentence is the wording of that text, revised from the “original, unopened container” wording of USP29–NF24 (2006). Regulatory document.
2. United States Pharmacopeia. General Chapter <341>, Antimicrobial Agents—Content. Quoted sentence taken from the USP31–NF26 Supplement 1 text; chapter current as USP–NF document USPNF_M99100_01_01, DOI 10.31003/USPNF_M99100_01_01. Regulatory document.
3. United States Pharmacopeia. General Chapter <797>, Pharmaceutical Compounding—Sterile Preparations, sections 14.5, 15.1–15.2 and 16.1. Regulatory document.
4. United States Pharmacopeia. Bacteriostatic Water for Injection (monograph): definition, packaging and storage, labelling, antimicrobial agent(s), bacterial endotoxins, pH. Regulatory document.
5. United States Pharmacopeia. Water for Injection (monograph). Regulatory document.
6. Hospira, Inc. Bacteriostatic Water for Injection, USP. Approved US prescribing information, NDA 018802, DESCRIPTION section; label revision 08/2019; NDC 0409-3977-03 at 0.9% and NDC 0409-1093-04 at 1.1%. Regulatory document.
7. European Pharmacopoeia. General text 5.1.3, Efficacy of antimicrobial preservation (01/2011:50103), including Table 5.1.3.-1. Regulatory document.
8. European Pharmacopoeia. Parenteral preparations, monograph 0520, as reproduced in the British Pharmacopoeia: LABELLING list, and the Multidose preparations and Containers and closures provisions. Regulatory document.
9. Pharmacopoeial Discussion Group. Harmonised monograph Benzyl Alcohol (Ph. Eur. 0256 / USP–NF / JP), adoption stage 6. Regulatory document.
10. Committee for Proprietary Medicinal Products and Committee for Veterinary Medicinal Products. Note for Guidance on Inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products. CPMP/CVMP/QWP/115/95, 1997. Regulatory document.
11. Committee for Proprietary Medicinal Products. Note for Guidance on In-Use Stability Testing of Human Medicinal Products. CPMP/QWP/2934/99, 2001. Regulatory document.
12. European Commission. Commission Delegated Regulation (EU) 2024/197 of 19 October 2023 amending Regulation (EC) No 1272/2008 as regards harmonised classification and labelling of certain substances; Annex VI Table 3, index number 603-057-00-5, benzyl alcohol (EC 202-859-9, CAS 100-51-6): Acute Tox. 4 (H302), Eye Irrit. 2 (H319), Skin Sens. 1B (H317); pictogram GHS07, signal word Warning. Applicable from 1 September 2025. Regulatory document.
13. National Center for Biotechnology Information. PubChem Compound Summary for CID 244, benzyl alcohol. Reference database.
14. Meyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. J Pharm Sci. 2007;96(12):3155–67. PMID 17722087. DOI 10.1002/jps.20976. Review.
15. Yano T, Miyahara Y, Morii N, Okano T, Kubota H. Pentanol and benzyl alcohol attack bacterial surface structures differently. Appl Environ Microbiol. 2016;82(1):402–8; epub 30 October 2015. PMID 26519389. DOI 10.1128/AEM.02515-15. In vitro.
16. Roy S, Jung R, Kerwin BA, Randolph TW, Carpenter JF. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations. J Pharm Sci. 2005;94(2):382–96. PMID 15614819. DOI 10.1002/jps.20258. In vitro.
17. Thakare V, Mayr B, Artenjak A, et al. Investigation of drug product and container-closure interactions: a case study of diluent containing prefilled syringe. Eur J Pharm Biopharm. 2019;140:67–77. PMID 31051250. DOI 10.1016/j.ejpb.2019.04.018. In vitro.
18. Kazemifard AG, Moore DE, Mohammadi A, Kebriyaeezadeh A. Capillary gas chromatography determination of benzaldehyde arising from benzyl alcohol used as preservative in injectable formulations. J Pharm Biomed Anal. 2003;31(4):685–91. PMID 12644195. DOI 10.1016/s0731-7085(02)00729-x. In vitro.
19. Lai MC, Topp EM. Solid-state chemical stability of proteins and peptides. J Pharm Sci. 1999;88(5):489–500. PMID 10229638. DOI 10.1021/js980374e. Review.
20. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–75. PMID 20143256. DOI 10.1007/s11095-009-0045-6. Review.
21. Lachman L, Weinstein S, Hopkins G, Slack S, Eisman P, Cooper J. Stability of antibacterial preservatives in parenteral solutions. I. Factors influencing the loss of antimicrobial agents from solutions in rubber-stoppered containers. J Pharm Sci. 1962;51:224–32. PMID 14461376. DOI 10.1002/jps.2600510308. In vitro.
22. Lachman L, Weinstein S, Urbanyi T, Ebersold E, Cooper J. Stability of antibacterial preservatives in parenteral solutions. III. Relationship between chemical loss and microbiological activity in multiple-dose vials. J Pharm Sci. 1963;52:241–3. PMID 13927917. DOI 10.1002/jps.2600520311. In vitro.
23. Lachman L, Urbanyi T, Weinstein S. Stability of antibacterial preservatives in parenteral solutions. IV. Contribution of rubber closure composition on preservative loss. J Pharm Sci. 1963;52:244–9. PMID 13927916. DOI 10.1002/jps.2600520312. In vitro.